MAYO-MC0672 (NCI Trial)

Intravenous Administration of REOLYSIN® for Patients with Metastatic Melanoma

In August 2008, Oncolytics announced that the US National Cancer Institute (NCI) had started enrollment in a Phase II trial for patients with metastatic melanoma using systemic administration of REOLYSIN^®.  Patients would receive systemic administration of REOLYSIN^® at a dose of 3 x 10¹⁰ TCID₅₀ per day on days one through five of each twenty-eight day cycle, for up to twelve cycles of treatment.
 
The primary objectives of the study were to assess the antitumor effects of REOLYSIN^® in patients with metastatic malignant melanoma, as well as the safety profile of REOLYSIN^®. Secondary objectives included assessment of progression free survival and overall survival.
 
The NCI sponsored the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics provided clinical supplies of REOLYSIN^®. The Principal Investigator is Dr. Evanthia Galanis of the Mayo Clinic Cancer Center.
 
 
Links:

• August 7, 2012: Phase II Trial of Intravenous Administration of Reolysin^® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma (PDF)

• October 23, 2008: Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium (Press Release)

• August 12, 2008: US NCI Starts Enrollment in Phase II Systemic Melanoma Clinical Trial with REOLYSIN^® (Press Release)

• May 14, 2007: US NCI Files for Phase II Systemic Melanoma Trial with REOLYSIN^® (Press Release)

• January 18, 2006: Oncolytics Biotech Inc. Announces Commencement of Solicitation Process for Clinical Trials Sponsored by the US National Cancer Institute (Press Release)

• October 29, 2003: Oncolytics Biotech Inc. and the US National Cancer Institute to Collaborate on Multiple Clinical Trials with REOLYSIN^® (Press Release)